Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III clinical trial assessing R-phenserine in patients with Alzhiemer's disease

Next Previous
X
Search
Trial Profile

Phase III clinical trial assessing R-phenserine in patients with Alzhiemer's disease

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 08 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Buntanetap (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Annovis Bio

    • Most Recent Events

    • 06 May 2024 According to Annovis media release, the Phase II/III study provided with valuable information for an improved Phase III pivotal trial. The study will prescreen patients for plasma AD biomarkers to confirm the diagnosis. Study will only enroll patients with early and mild Alzheimer's (MMSE 21-28), the subpopulation which showed the highest level of improvement after buntanetap, as seen from completed AD studies.
    • 05 Jan 2022 According to Annovis Bio medoia release, the Company expects guidance from the U.S. Food and Drug Administration (FDA) in Q1 of 2022 on the initiation of this phase 3 clinical trial.
    • 29 Nov 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top